Nuances in Efficacy, MACE Risk Revealed Between JAKi, TNFi

Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs TNF inhibitors, as well as their efficacy in patients with different levels of risk.

Related Keywords

Geneva ,Genè ,Switzerland ,Netherlands ,Berlin ,Germany ,Tubbergen ,Gelderland ,German ,Dutch ,Anja Strangfeld ,Eli Lilly ,Maya Buch ,Romain Aymon ,Manchester Biomedical Research Centre ,University Of Manchester ,Geneva University Hospitals ,European Alliance Of Associations ,German Rheumatism Research Center Berlin ,Pfizer ,University Medicine Berlin ,European Alliance ,Efficacy With ,Without History ,Biomedical Research Centre ,Medscape Medical News ,Merel Opdam ,Sint Maartenskliniek ,Real World Data Longitudinal Prescription ,Cv ,Ardiovascular ,Rheumatoid Arthritis ,A ,Remission ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Cardiovascular Disease ,Vd Cardiovascular Disease ,Disease Modifying Antirheumatic Drugs Dmards ,Mard Disease Modifying Antirheumatic Drug ,Europe ,European ,Patient History ,Medical History ,Arthritis ,Oint Inflammation ,Tu ,